Treatment News : First Rectal Gel Studies Show Real Promise - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 1, 2011

First Rectal Gel Studies Show Real Promise

by David Evans

Microbicide researchers announced success with a new rectal gel designed to cut HIV transmission, saying that early data suggests it could work quite well provided that they can figure out how to make it more compatible with the fragile cells that line the rectum. Those important tweaks are already in the works and were also reported Monday, February 28, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

In the first study, Peter Anton, MD, from the David Geffen School of Medicine at the University of California in Los Angeles presented data on behalf of his colleagues from the Microbicide Trials Network 006 (MTN-006) study. MTN-006 was designed to test how well a vaginal gel that demonstrated a roughly 40 percent reduction in new infection in women might work as a rectal gel for people who have anal sex.

The vaginal gel, manufactured by a company called CONRAD and containing a 1 percent solution of the antiretroviral (ARV) drug tenofovir—found in Viread, Truvada and Atripla—demonstrated superiority to a placebo in the CAPRISA 004 trial in 2010. Women who used the gel intermittently were about 39 percent less likely to become infected with HIV than women who used a gel that contained a placebo.

Researchers have been eager to fast-track an effective microbicide for rectal use, given that rates of HIV infection are so high among men who have sex with men in many parts of the world, and since anal sex—which plenty of women engage in as well—confers such a high risk for HIV transmission.

The first step in the process was to demonstrate whether the same gel that worked vaginally would have any potential as a rectal gel. To determine this, Anton and his colleagues recruited 14 men and 4 women, all HIV-negative, to try the gel rectally and see whether the it was safe and whether cells taken from participants’ rectums after the gel was applied would be resistant to HIV infection. Anton’s team were also curious how likely people who tried the gel would be to use it for anal sex in the future.

In terms of potential effectiveness, Anton’s group first looked at how well the gel got into the cells of the rectum and to the blood stream, and compared this with tenofovir taken orally, which is also being tested for its HIV-prevention potential. The group found that while very little of the drug in gel form made it into the blood stream—which is actually a good thing as this could increase the risk of side effects—concentrations in the rectum were many times higher with the gel compared with people who took the oral version.

Anton and his colleagues next looked at cells taken from the rectums of people who used the gel or the oral form of tenofovir and examined whether those cells were either more or less susceptible to being infected with HIV in test tubes.

Strikingly, the team found that when people took the oral version of tenofovir, their cells were not resistant to infection. The same was true when they looked at cells taken after only a single application of the gel rectally. When people applied the gel every day for seven days, however, the cells taken from their rectums were much more resistant to infection. This, said Anton, offers strong signals that the gel could work for anal sex as it did for vaginal sex.

All didn’t go smoothly, however. Only 25 percent of the people who used the tenofovir gel said they liked it, compared with 50 percent of the people who received a placebo gel—though most indicated that they would still use it if it were shown to be effective. Also, the tenofovir gel caused some unpleasant side effects in some of the participants’ lower intestinal tract.

“These results tell us that tenofovir gel was relatively safe to use in the rectum for most participants, but we need to address side effects to make it more acceptable to use,” Anton said. “Even though three quarters of the participants reported they didn’t like the gel, we are very encouraged that the majority would consider using such a product in the future.”

When the group looked for an explanation for the side effects, Anton and his colleagues realized that the tenofovir gel was causing an imbalance in the chemicals inside and outside of the rectal cells, causing those cells to expel water and become damaged (a process called osmolality). This meant that the specific tenofovir gel used in the study really couldn’t ever be offered in real world conditions.

Fortunately, one of Anton’s colleagues, Charlene Dezzutti, PhD, from the University of Pittsburgh, is already working on an improved version of the tenofovir gel. Her team published a poster at CROI documenting their progress on the improved gel so far in test tubes.

By reducing the amount of silicon in the gel, Dezzutti’s team reduced the osmolality of the gel and made it potentially much safer and less irritating for rectal cells. The new formulation, however, is just as effective at fighting HIV as the old gel. The next step, according to the Microbicide Trials Network, will be to study the new gel formulation under the same conditions as the old one, and that study is already underway at three sites in the United States.

Search: Rectal gel, tenofovir, CAPRISA, microbicide, men, anal sex, rectum, Microbicide Trials Network, osmolality, MTN-006, MTN-007, Peter Anton, Charlene Dezzutti, HIV prevention, transmission


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 2 (of 2 total)    

Don, Erie, Pennsylvania, 2011-03-03 15:45:35
Are studies also being done with regard to how the gel might offer protection to an HIV negative inserting partner?

Derrick Wheeler, Atlanta, GA, 2011-03-03 14:32:37
Thanks to the doctors, scientists, and researchers committed to stopping this pandemic. Please keep up the good fight and continue to keep us informed.

comments 1 - 2 (of 2 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    romanticseattle
    Tacoma
    Washington


    sefarady
    New York
    California


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.